Navigation Links
Cumberland Pharmaceuticals Launches Caldolor(R) in the United States for Treatment of Pain and Fever
Date:9/9/2009

NASHVILLE, Tenn., Sept. 9 /PRNewswire-FirstCall/ -- Cumberland Pharmaceuticals Inc. (Nasdaq: CPIX) announced today that it has successfully implemented the U.S. launch of Caldolor((R)), an intravenous formulation of ibuprofen, designed primarily for use in the hospital setting. Caldolor is the first and only injectable product available in the United States for the treatment of pain and fever. Cumberland received U.S. Food and Drug Administration marketing approval for Caldolor in June 2009. The product is now fully stocked at the wholesalers serving hospitals nationwide, and is available in both 400mg and 800mg vials.

"We are pleased to introduce Caldolor ahead of schedule, offering a new level of patient care as ibuprofen advances to IV," said A.J. Kazimi, Cumberland's Chief Executive Officer. "We have worked diligently over the past year to prepare for the introduction of Caldolor to physicians and patients as the only injectable product available in the United States for reduction of fever, and as an important alternative for single-agent and multi-modal pain management."

In preparation for the product launch, Cumberland conducted comprehensive market research, prepared a full package of educational materials, optimized hospital coverage and recently launched the product website. Caldolor will be supported by 113 experienced sales professionals across the country, comprised of Cumberland's recently expanded hospital sales force of 77 representatives and managers as well as its field sales force of 36 representatives and managers. Cumberland has also expanded its professional affairs group to handle medical inquiries about the product.

"The introduction of IV ibuprofen (Caldolor) should allow anesthesiologists to a
'/>"/>

SOURCE Cumberland Pharmaceuticals Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7

Related medicine news :

1. Orion ICG, LLC Announces Acquisition of Cumberland Therapy Services, Inc.
2. Cumberland Pharmaceuticals Announces Appointments
3. Cumberland Pharmaceuticals to Announce Second Quarter 2009 Financial Results on August 27, 2009
4. Cumberland Pharmaceuticals Reports Second Quarter 2009 Financial Results
5. Cumberland Pharmaceuticals to Present at UBS Global Life Sciences Conference in New York on September 21, 2009
6. Arena Pharmaceuticals to Present at the NewsMakers in the Biotech Industry Conference
7. Schering-Plough/Merck Pharmaceuticals Announce FDA Filing Acceptance of New Drug Application for Loratadine/Montelukast Tablet
8. Provectus Pharmaceuticals, Inc. Begins Phase 2 Clinical Trial for Metastatic Melanoma
9. Idenix Pharmaceuticals to Present at Two Upcoming Investor Conferences
10. Vista Partners Updates Coverage on Tapestry Pharmaceuticals
11. Transcept Pharmaceuticals, Inc. to Present at UBS 2007 Global Life Sciences Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/22/2014)... (EGFR) mutations found in the circulating free tumor DNA ... cancer (NSCLC) patients correlates well with the EGFR mutations ... inhibitor (TKI) therapy is approved for EGFR activating mutation ... determining mutation status is with DNA derived directly from ... A more abundant and less invasive source of tumor ...
(Date:8/22/2014)... DC (PRWEB) August 22, 2014 Paying ... little easier in the coming year for four nurse ... the National League for Nursing Foundation for Nursing ... – will share $28,000, $10,000 more than in 2013, ... Ann Kerr Endowment and Elizabeth Isaac Marcil Endowment Funds, ...
(Date:8/22/2014)... August 22, 2014 Advancements in ... some clinical applications due to their cost-effectiveness, non-invasiveness, ... innovations in ultrasound, such as the evolution of ... to keep the market moving throughout 2014 and ... can enhance not only the point-of-care (POC) testing ...
(Date:8/22/2014)... Eagerly embracing intended parents around the ... now offers the top male infertility programs — run ... fertility network of IVFinMexico.com continues to shape ... care, female and male infertility, advanced research and education. ... so eminently set by company CEO and Founder Tolga ...
(Date:8/22/2014)... (PRWEB) August 22, 2014 CarePoint ... specialist in Internal Medicine, Geriatrics, Hospice and Palliative ... CarePoint Health Medical Group. Their system welcomes Dr. ... and experienced physicians comprise CarePoint Health Medical Group, ... in Hudson County, representing a wide range of ...
Breaking Medicine News(10 mins):Health News:High concordance between EGFR mutations from circulating-free tumor DNA and tumor tissue in non-small cell lung cancer 2Health News:NLN Foundation for Nursing Education Announces 2014 Faculty Scholarship Awards 2Health News:NLN Foundation for Nursing Education Announces 2014 Faculty Scholarship Awards 3Health News:Global Top Ultrasound Market Suppliers Assessed in New VPG Research Report Available at MarketPublishers.com 2Health News:Global Top Ultrasound Market Suppliers Assessed in New VPG Research Report Available at MarketPublishers.com 3Health News:Mexico Now Offers Top Program for Couples Suffering from Male Infertility 2Health News:Mexico Now Offers Top Program for Couples Suffering from Male Infertility 3Health News:Mexico Now Offers Top Program for Couples Suffering from Male Infertility 4Health News:Dr. Reisner Joins CarePoint Health Medical Group 2
... ReBuilder Medical,Technologies, Inc. (Pink Sheets: RBRM), announces ... ), "We have leased, fitted and established ... will allow us to streamline the process,of new ... facility will house,both electronic and pharmaceutical laboratories," announced ...
... &, Presidential Election May Mean for Private Equity in 2008, Jan. ... the ... credit markets in,turmoil, the economy in a seeming slowdown and a presidential ... Outlook,Conference on January 29-30 at the Grand Hyatt in New York to ...
... men with chronic anxiety are at substantially higher risk, experts ... who suffer from chronic anxiety substantially increase their risk of ... stress has been linked to an increased risk of heart ... been identified as a risk factor also. , "There is ...
... 2 diabetes are often advised to cut out sucrose (table ... has been questioned by some researchers who suggest that moderate ... the diet of patients with diabetes. Now a new study ... It showed that patients who increased their daily sugar intake ...
... tendon grafts loaded with gene therapy may soon ... that has eluded surgeons to date. According to ... Therapy, a new graft technique may provide the ... can reorganize as it heals. Such tissue-engineering approaches ...
... Haemonetics,Corporation (NYSE: HAE ) will announce its Q3FY08 earnings on January ... Conference Call Dial-In Information (888) 802-8577 ... ID: 30405896 This call will be ... dial:, (800) 642-1687 (US & Canada) ...
Cached Medicine News:Health News:ReBuilder Medical Technologies, Inc. Expands R&D of New Products 2Health News:Private Equity's Top Execs to Share Advice, Candid Predictions at 2008 Outlook Conference 2Health News:Anxiety Raises Heart Attack Risk 2Health News:Anxiety Raises Heart Attack Risk 3Health News:Carrot cake study on sugar in type 2 diabetes 2Health News:Freeze-dried tendon implants prove effective in early studies 2Health News:Freeze-dried tendon implants prove effective in early studies 3Health News:Freeze-dried tendon implants prove effective in early studies 4Health News:Freeze-dried tendon implants prove effective in early studies 5
(Date:8/22/2014)... Aug. 22, 2014 /CNW/ - On Aug. 20, at ... the Canadian Medical Association (CMA) voted on and approved ... material, including medicinal cannabis. Bedrocan Cannabis Corp., a leading ... the CMA motion. The CMA is quite ... associated with smoking any plant material, including medicinal cannabis. ...
(Date:8/22/2014)... CHICAGO , Aug. 22, 2014   Zacks Equity Research ... the Bull of the Day and Panera (Nasdaq: PNRA - ... Zacks Equity Research provides analysis on Amicus Therapeutics (Nasdaq: FOLD ... ) and Shire (Nasdaq: SHPG - Free Report ). ... Bull of the Day : The ...
(Date:8/22/2014)... COLORADO SPRINGS, Colo. , Aug. 22, 2014 ... Company specializing in cannabis formulation-based drug development and ... of UFCM iCare,s third international medical cannabis conference ... Strasbourg, France , on October ... experts with other stakeholders, such as researchers, health ...
Breaking Medicine Technology:Bedrocan Canada Statement Regarding Canadian Medical Association Motion on Smoking Marijuana 2Epizyme, Panera, Amicus Therapeutics, Sanofi and Shire highlighted as Zacks Bull and Bear of the Day 2Epizyme, Panera, Amicus Therapeutics, Sanofi and Shire highlighted as Zacks Bull and Bear of the Day 3Epizyme, Panera, Amicus Therapeutics, Sanofi and Shire highlighted as Zacks Bull and Bear of the Day 4Epizyme, Panera, Amicus Therapeutics, Sanofi and Shire highlighted as Zacks Bull and Bear of the Day 5Epizyme, Panera, Amicus Therapeutics, Sanofi and Shire highlighted as Zacks Bull and Bear of the Day 6Cannabis Science, Inc. (CBIS) to Sponsor 3rd International Conference on Cannabinoids in Medicine in October 2014 in Strasbourg, France 2Cannabis Science, Inc. (CBIS) to Sponsor 3rd International Conference on Cannabinoids in Medicine in October 2014 in Strasbourg, France 3
... 22, 2011 ResearchDx announced today the official ... CDO. Recent FDA initiatives, such ... Co-Development Concept Paper, have spurred biopharmaceutical companies, interest ... companion diagnostics. The traditional Contract Research Organization (CRO), ...
... OMER ) today announced that its exclusive license to ... been amended to include addiction and compulsive disorders in the ... Company,s discovery of a previously unknown link between PDE7 and ... it also is the first to link PDE7 to any ...
Cached Medicine Technology:ResearchDx Launches Contract Diagnostics Organization (CDO) 2Omeros Announces Expansion of Exclusive License to PDE7 Inhibitors from Daiichi Sankyo 2Omeros Announces Expansion of Exclusive License to PDE7 Inhibitors from Daiichi Sankyo 3Omeros Announces Expansion of Exclusive License to PDE7 Inhibitors from Daiichi Sankyo 4
... combination of the Aliquoting System RSD 800A ... ACM-8). This turns out in an efficient ... laboratory. The System automates all important front-end ... via cap identification, sample quality control, decapping, ...
... The Aliquoting System RSD 800A is an ... and archiving (additional tube type identification via ... to process various sample tubes in a ... sorting areas are customized and offer high ...
... Sorting System RS 800 can sort different ... manual sorting are not necessary anymore and ... in a very timesaving and economical way ... Optionally a Tube Type Identification via Cap ...
... MGB Alert Detection Reagents provide molecular labs ... based assays. By using our MGB technology, ... Nanogen is now able to provide molecular ... acid sequences of specific organisms or genetic ...
Medicine Products: